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Abstract
Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer with high metastatic
potential. Most patients have lymph node involvement at the time of diagnosis and 1/3 of the patients have distant
metastases. In a previous study, we demonstrated that IBC is a distinct form of breast cancer in comparison with non-
IBC. The aim of this study was to investigate the presence of the different molecular subtypes in our data set of 16
IBC and 18 non-IBC specimen. Therefore, we selected an ‘intrinsic gene set’ of 144 genes, present on our cDNA chips
and common to the ‘intrinsic gene set’ described by Sorlie et al. [PNAS, 2003]. This set of genes was tested for
performance in the Norway/Stanford data set by unsupervised hierarchical clustering. Expression centroids were
then calculated for the core members of each of the five subclasses in the Norway/Stanford data set and used to
classify our own specimens by calculating Spearman correlations between each sample and each centroid. We
identified the same cell-of-origin subtypes in IBC as those already described in non-IBC. The classification was in
good agreement with immunohistochemical data for estrogen receptor protein expression and cytokeratin 5/6
protein expression. Confirmation was done by an alternative unsupervised hierarchical clustering method. The
robustness of this classification was assessed by an unsupervised hierarchical clustering with an alternative gene set of
141 genes related to the cell-of-origin subtypes, selected using a discriminating score and iterative random permu-
tation testing. The contribution of the different cell-of-origin subtypes to the IBC phenotype was investigated by
principal component analysis. Generally, the combined ErbB2-overexpressing and basal-like cluster was more ex-
pressed in IBC compared to non-IBC, whereas the combined luminal A, luminal B and normal-like cluster was more
pronounced in non-IBC compared to IBC. The presence of the same molecular cell-of-origin subtypes in IBC as in
non-IBC does not exclude the specific molecular nature of IBC, since gene lists that characterize IBC and non-IBC
are entirely different from gene lists that define the different cell-of-origin subtypes, as evidenced by principal
component analysis.
Introduction
Breast cancer is a major cause of morbidity and mor-
tality [1], characterized by heterogeneity in its natural
history and in the responsiveness to treatments. To
tackle this heterogeneity of breast cancer, a cell-of-origin
classifier was described and identified five cell-of-origin
subtypes related to mammary epithelial biology: luminal
A, luminal B, basal-like, ErbB2-overexpressing, and
normal-like [2,3,4]. These molecular subtypes have been
associated with different histoclinical features including
clinical outcome. Specific genome alterations and
distinct gene expression changes in response to chemo-
therapy have been associated to some subtypes, further
suggesting that these molecular subtypes represent dis-
tinct diseases [5,6]. Recently, some of the cell-of-origin
subtypes have been associated with cancer stem cell
biology [7].
Inflammatory breast cancer (IBC) is the most lethal
form of breast cancer, characterized by a very aggressive
behavior and high metastatic potential. At time of
diagnosis most women have axillary lymph node
involvement and 1/3 of the patients have metastases in
distant organs. The disease presents at a younger age
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than non-IBC, with a rapidly progressing inflammatory
tumor associated redness, warmth, pain, induration and
edema. A palpable tumor mass is not necessarily present
[8]. Tumor emboli in dermal lymphatics may be appar-
ent on skin biopsy, but, in the absence of clinical find-
ings do not indicate IBC. Hence, IBC is primarily a
clinical diagnosis, classified T4d in the TNM classifica-
tion of the American Joint Committee on Cancer [9].
About two-thirds of the IBC tumors are of high histo-
logical grade, a ratio far higher than in non-IBC. Given
the high histological grade, IBC is more frequently
estrogen receptor (ER)-negative than non-IBC and up
to 60% lack hormone receptor expression, whereas other
forms of locally advanced breast cancer (LABC) are
more likely to be ER-positive [8]. In addition, the
prevalence of the TP53 mutation as well as the preva-
lence of the amplification of the ErbB2 oncogene were
found to be much higher in IBC compared to non-IBC
[10]. Despite advances in the multidisciplinary treat-
ment, the prognosis of IBC is less favorable than of non-
IBC, with a 3-year survival of about 40% [8]. Because of
its relative scarcity and difficulty of obtaining diagnostic
samples of sufficient size, little is known about the
molecular basis of IBC. The study of the molecular
mechanisms of IBC can, however, lead to new thera-
peutic targets, and, to insight in mechanisms of motility
and metastasis of breast cancer cells.
Recently, both in vivo and in vitro experiments have
identified genes that contribute to the aggressive
phenotype of IBC. Overexpression of RhoC GTPase is
observed in over 90% of IBC in contrast to 36% of non-
IBC [11,12]. Overexpression of RhoC in human mam-
mary epithelial (HME) cell lines nearly recapitulated the
IBC phenotype with regards to invasion, motility [13]
and production of angiogenic growth factors [14]. Acti-
vation of the mitogen activated protein kinase (MAPK)
pathway was responsible for these features, whereas
anchorage independent growth was induced through the
Phosphatidyl Inositol 3-phosphate Kinase (PI3K) path-
way [15]. Addition of a farnesyl transferase inhibitor led
to the reversion of the RhoC-induced inflammatory
breast cancer phenotype [16]. Moreover, expression of
WISP3, a tumor growth and angiogenesis inhibitory
protein, is lost in over 90% of the IBC tumors [17]. It has
been shown that WISP3 attenuates RhoC protein
expression in HME cell lines and in the SUM149 IBC cell
line, through the modulation of IGF signaling, inducing
opposite changes in invasive, motile and angiogenic
characteristics. Loss of WISP3 again recapitulates the
IBC phenotype [17,18,19]. In addition to the modulation
of angiogenic parameters by RhoC and WISP3, in-
creased angiogenesis in IBC was evident by both an in-
creased number of microvessels and a higher fraction of
proliferating endothelial cells [20]. Increased expression
of several angiogenic and lymphangiogenic growth fac-
tors and growth factor receptors in IBC compared to
non-IBC was demonstrated by quantitative real-time
RT-PCR [21]. These findings suggest that IBC consti-
tutes a subset of breast carcinoma with a specific biology.
Despite the recent advances in characterizing the
molecular basis of IBC, much remains to be elucidated.
Therefore genome-wide expression profiling has been
performed to investigate additional mechanisms con-
tributing to the biology of IBC [22,23]. We have
identified a molecular signature, based on the expres-
sion of 756 genes, using 16 IBC and 18 non-IBC
specimens. Application of this molecular signature by
unsupervised hierarchical clustering methods resulted
in a perfect separation of IBC and non-IBC specimens.
In the list of differentially expressed genes a high
number of NF-kappaB target genes as well as up-
stream activators of the NF-kappaB pathway (IL1 and
Toll Like Receptor pathways) were found. Using a
class prediction method based on the expression of 50
genes, we were able to assign 14/16 (87%) IBC and
non-IBC samples to the correct class. In addition, we
found an increased expression of markers representing
the breast basal-like cell-of-origin subtype in IBC.
Conversingly, markers representing the luminal A cell-
of-origin subtype were more pronounced in non-IBC.
In agreement with the findings of specific molecular
alterations in IBC tumor samples, these data suggested
that IBC and non-IBC have to be regarded as two
separate entities with important diagnostic and thera-
peutic consequences [23].
The objective of this study was to determine to which
extent the cell-of-origin subtypes, as described by Sorlie
et al. [4], determine the specific phenotype of IBC. These
cell-of-origin subtypes have been studied once in IBC
[24]. In this study the cell-of-origin subtype profile did
not discriminate IBC from non-IBC. The present study
indicates that the IBC phenotype is mainly determined
by a set of genes independent of the gene sets that define




Breast cancer samples were obtained from 34 patients
with breast adenocarcinoma treated in the General
Hospital Sint-Augustinus, Wilrijk, Belgium. Each pa-
tient gave written informed consent. Samples were
stored in liquid nitrogen within 15 min after excision.
Thirty-four samples included 16 pretreatment samples
of patients with IBC, diagnosed by strictly respecting
the criteria mentioned in the TNM classification of the
American Joint Committee on Cancer as T4d [9]. The
presence of tumor emboli in dermal lymphatics was, as
an isolated pathological finding, not sufficient for the
diagnosis of IBC. Of the 18 non-IBC samples, 10
represented LABC (7 T3, 3 T4a), 3 samples represented
T2-tumors, and five represented T1-tumors. Thirteen
patients with non-IBC had pathological axillary lymph
node involvement.
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RNA Isolation, processing and cDNA microarray
hybridization
RNA was isolated and processed as described before
[23], using the RNeasy Mini Kit (Qiagen, Valencia, CA,
USA). High quality RNA was reverse transcribed,
amplified and Cy5 labeled using the Amino Allyl Mes-
sageAmp aRNA kit (Ambion Inc., Austin, TX, USA).
Universal Human Reference RNA (Stratagene, La
Jolla, CA, USA) was processed similarly and Cy3 la-
beled for competitive hybridization. cDNA chips were
obtained from the Sanger Center and hybridized during
16 h at 47 C in a volume of 40 ll. Information
regarding the clone set and the microarray production
can be obtained from the world wide web: www.san-
ger.ac.uk/Projects/Microarrays. After hybridization,
slides were washed and scanned immediately using
ScanArray software. Data were generated using
QuantArray software. The methodology has been de-
scribed in Van Laere et al. [23].
Data analysis
Biologically relevant subtypes of non-IBC have been
defined using an ‘intrinsic’ set of 500 genes [2,3,4].
These genes were selected from a group of 8000 genes,
based on a lower variation in expression between paired
samples from the same patients than between samples
from different patients. To test the generality of these
subtypes in our series of samples, we analyzed our
samples with genes common to the intrinsic gene set and
ours. Of the 500-gene set used by Sorlie et al. [4], 165
genes were present on our chip represented by 240
clones. To prevent batch related clustering, genes with a
batch related gene expression difference were filtered
out. This resulted in a gene set of 144 genes represented
by 200 clones.
Prior to analyzing our series of samples using the
reduced intrinsic set of genes, we first investigated
whether these 144 genes were still able to identify five
cell-of-origin subtypes, and their associated gene clusters
in breast cancer. Therefore, we submitted the Norway/
Stanford series of 122 breast tissue samples to hierar-
chical clustering based on the expression of the 144 gene
set, represented by 150 clones in the original Norway/
Stanford data set. Normalized and log2 transformed
expression data for 150 clones were extracted, median-
centered on genes and analyzed using unsupervised
hierarchical clustering with Pearson correlation as sim-
ilarity metric. Clustering was visualized using TreeView
(freeware, http://rana.lbl.gov/EisenSoftware.htm).
For each cell-of-origin subtype, we subsequently
computed the typical expression profile for the 144
genes, hereafter designated centroid. The samples from
the luminal A, the ErbB2-overexpressing, and the basal
centroids were easily defined based on the expression
pattern for the ER, the ErbB2, and the basal gene
clusters, respectively, and by selecting tumors with the
highest correlation with each other within the subgroup.
The samples for the normal, and the luminal B centroids
were defined based on their clustering as a separate node
in the dendrogram, representing tumor samples with a
high correlation with each other within the subgroup.
The centroid expression for each of the five tumor
subgroups was calculated as the average expression for
each of the 144 genes in the corresponding samples.
Centroid expression for genes represented by multiple
clones was calculated by averaging the centroid expres-
sion of the representing clones. The classification power
of the centroids was tested by classifying the remaining
samples (n = 56) from the Norway/Stanford data set by
calculating Spearman correlation coefficients between
each remaining sample and each centroid. The samples
were classified according to the highest correlation
coefficient between a sample and a centroid.
In order to identify cell-of-origin groups in our series
of breast tumor samples, normalized gene expression
data for 200 clones, representing 144 genes were ex-
tracted from our data set. Gene expression data for
multiple clones representing a single gene were averaged.
Next, data were log2 transformed and median centered
on genes. In order to classify our breast tumor samples,
Spearman correlations were calculated between each
sample in our series and each centroid based on the
Norway/Stanford data set. Again, a breast tumor sam-
ple was classified according to the highest correlation
coefficient between its molecular profile and any of the
calculated centroids. Unsupervised hierarchical cluster-
ing, with data median-centered on genes, average link-
age clustering, and the Pearson correlation coefficient as
similarity metric was applied to investigate the reliability
of the subtype classification.
To investigate the robustness of this classification,
supervised analysis was applied to identify genes that
discriminate between the cell-of-origin subtypes. Each
subtype was compared with the others by using a dis-
criminating score (DS) combined with iterative random
permutation testing. The DS was calculated for each
gene [25] as DS = (M1)M2)/(S1 + S2), where M1
and S1, respectively, represent mean and SD of expres-
sion levels of the gene in subgroup 1, and M2 and S2 in
subgroup 2. Confidence levels were estimated by 200
iterative random permutations of samples as previously
described [26] with a significance threshold of 0.05. The
final list of discriminator genes for the analysis included
at most the 15 top-ranked genes identified as discrimi-
nator in at least one comparison of cell-of-origin groups.
Selection of the list of discriminator genes was per-
formed using GeneCluster 2.0 (Broad Institute, Cam-
bridge, MA, USA). Once identified, the classification
power of the discriminator signature was illustrated by
performing unsupervised hierarchical clustering using
data median-centered on genes, Pearson correlation as
similarity metric and average-linkage clustering using
GeneSpring software (Silicon Genetics, Redwood City,
CA, USA).
To identify to which extent the different cell-of-origin
subtypes are responsible for the variability seen in the
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entire data set, we executed a principal component
analysis (PCA) for the five cell-of-origin subtypes on a
gene list with 5914 non-batch-related genes, using
GeneSpring software. In a second approach we investi-
gated to what extent the different cell-of-origin subtypes
characterize IBC. Therefore, PCA was executed for the
same five subgroups on a gene lists with 953 genes with a
statistically significant (p<0.05), 1.5-fold difference in
expression level between IBC and non-IBC. PCA is a
decomposition technique that produces a set of expres-
sion patterns (eigenvectors) known as the principal
components. Each principal component is associated
with a value (eigenvalue) representing the amount of
variability explained by that expression pattern. The
expression pattern with the largest value is the first
principal component, the expression pattern with the
second largest value is the second principal component,
and so on. Once the principal components were identi-
fied we executed unsupervised hierarchical clustering
with genes strongly correlated (r>0.95) with any of the
principal components to investigate common biological
themes defined by the principal components.
Immunohistochemistry (IHC)
ER-alpha protein expression was detected by the anti-
body clone ID5 (M7047, DakoCytomation, Glostrup,
Denmark). Tumors were regarded as ER-alpha-positive
when at least 10% of the tumor cells had nuclear protein
expression. Staining was done on biopsy specimens used
for diagnosis in the surgical pathology lab of the Gen-
eral Hospital Sint-Augustinus. Scoring was done by a
surgical pathologist (P.B.V.).
Cytokeratin 5/6 (CK5/6) protein expression was de-
tected with the monoclonal antibody, clone D5/16 B4
(M7237, DakoCytomation, Glostrup, Denmark). For-
malin fixed, paraffin embedded tissue sections from 16
IBC and 18 non-IBC were rehydrated through sequen-
tial changes of alcohol and distilled water. Antigen re-
trieval was performed for 30 min in citrate buffer (pH 6)
at 95 C. Sections were incubated with the primary
antibody for 1 h at room temperature using a dilution of
1400 lg/l. The Dako Envision system on the Dako
Cytomation autostainer was used for visualization of
antibody binding. Tumor samples were regarded CK5/
6+ when tumor cells showed membranous or cyto-
plasmic staining.
Statistical analysis
Statistical analyses were done using SPSS software
(SPSS Inc., version 12.0). The fraction of the combined
luminal A, luminal B and normal-like cluster in IBC and
non-IBC was compared with the fraction of the com-
bined basal-like and ErbB2-overexpressing cluster in
IBC and non-IBC by using v2 test. Correlations between
immunohistochemical data for ER en CK5/6 and sam-
ple groups were studied by Fisher’s exact test or v2 test
when appropriate.
Results
Selection of a common intrinsic gene set and performance
in the Norway/Stanford tumors
One hundred and sixty-five genes, represented by 240
clones, were common to our cDNA chip and the
‘intrinsic gene set’ used by Sorlie et al. [4] to identify
five molecular subtypes in breast cancer. After exclu-
sion of 21 genes with a batch related gene expression
profile, 144 genes represented by 200 clones, were left
over. We investigated whether these 144 genes were still
able to discriminate between the same five cell-of-origin
subtypes in the Norway/Stanford series. Gene expres-
sion data for 122 breast tissue samples from the
Norway/Stanford data set were retrieved from the
world wide web (http://genome-www.stanford.edu/
breast_cancer/robustness/) and submitted to hierarchi-
cal clustering using data median-centered on genes,
average linkage clustering and Pearson correlation
coefficient as similarity metric. Results are shown in
Figure 1. Gene clustering revealed groups of coordi-
nately expressed genes, some of which represented
known expression signatures corresponding to cell
types: the ‘ER cluster’, including ESR1, MUC1 and
SIAH2, playing a prominent role in the classification of
samples, the ‘ErbB2 cluster’ including ERBB2 and
GRB7, and the ‘basal cluster’ including KRT5,
TRIM29, S100A1, ANXA8 and FZD7. Samples clus-
tered in two main branches (left and right) and five
major subgroups. The left branch was composed of the
normal-like, the basal-like, ErbB2-overexpressing and
the luminal B subgroups, whereas the luminal A sam-
ples clustered in the right branch. The luminal A, ba-
sal-like and ErbB2-overexpressing clusters were
characterized by clear gene clusters (ER, basal and
ErbB2, respectively) as described above. Upon visual
inspection of the color-coded expression profile (Fig-
ure 1), the normal-like subgroup displayed a strong
expression of the ‘basal cluster’ and low expression of
the ‘ER cluster’. The cluster containing luminal B
samples was the only cluster that was poorly identified.
Out of 17 samples originally identified as belonging to
the luminal B cluster, only 9 samples clustered together
using gene expression data for our 144 ‘intrinsic genes’.
Hence, no gene cluster was evident, although the
luminal B subgroup did show lower expression of the
‘ER cluster’, compared to the luminal A subgroup.
Despite the limited number of genes, these subgroups
were very similar to those previously described and
84% of the Norway/Stanford samples clustered to-
gether in the same manner as described in the original
manuscript [4]. These data indicate that our gene set,
composed of 144 genes common to our cDNA chip
and the intrinsic gene set, was able to identify the
different cell-of-origin subtypes.
Expression centroids were then calculated for the
core members of each of the five subclasses in the
Norway/Stanford data set and used to classify our
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specimen. The core members for the luminal A, the
ErbB2-overexpressing and the basal centroids were
easily defined based on the expression pattern of the ER,
ErbB2 and the basal gene clusters, respectively, and by
selecting tumors with the highest correlation with each
other within the subgroup: 27 samples for luminal A
(correlation>0.43), 11 samples for ErbB2-overex-
pressing (correlation>0.47) and 16 samples for basal-
like (correlation>0.53). For the normal-like and
luminal B subgroups, respectively 8 (correlation>0.29)
and 5 (correlation>0.32) samples were chosen. Alto-
gether, 78% of the samples selected in this manner were
the same as those selected by Sorlie et al. [4] for calcu-
lating their centroid expressions. The basal centroid
proved to be the most homogeneous one. Centroid
expression for each of the five cell-of-origin subtypes
was calculated by averaging the expression for each of
the 144 genes in the corresponding samples.
The classification power of the centroids was then
assessed by classifying the remaining samples in the
Figure 1. Hierarchical clustering of the Norway/Stanford data set using 150 clones representing 144 genes common to the intrinsic gene set and
our cDNA chip. Data are presented in matrix format with rows corresponding to genes and columns corresponding to samples. The expression
level of each single gene is relative to its median across all samples, and is color coded red or green indicating genes above and below the median
expression level, respectively. The magnitude of deviation from the median is represented by the color saturation. Grey represents genes with
missing data. Based on the expression pattern of 144 genes, five cell-of-origin subgroups were clearly identified, three of which were represented by
a corresponding gene cluster. The clusters are indicated by the colored bars beneath the dendrogram: luminal A (blue), normal-like (red), basal-
like (yellow), ErbB2-overexpressing (purple), and Luminal B (green). Branches of the core samples used for calculation of the centroid expressions
are similarly color coded. The corresponding gene clusters for luminal A, basal-like and ErbB2-overexpressing samples are indicated on the right:
luminal A (blue), basal-like (yellow) and ErbB2-overexpressing (purple).
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Norway/Stanford data set. In total, 70% (39/56) of the
remaining samples were assigned to the same cell-of-
origin subtype as described by the authors in the original
manuscript [4]. All of the basal-like (3/3), 77% of the
ErbB2-overexpressing samples (10/13), 66% of the
luminal A and the normal-like samples (18/27 and 2/3,
respectively), and 60% of the luminal B samples (6/10)
were correctly assigned to a cell-of-origin subtype with
the centroid classification method.
Identification of cell-of-origin subtypes in inflammatory
breast cancer
After calculating the centroid expression profile for
each of the cell-of-origin subtypes, we looked for
common themes in our series of 34 breast cancer
samples (16 IBC and 18 non-IBC). We calculated
Spearman correlations between each sample and each
centroid. A breast tumor sample was classified
according to the highest correlation of its molecular
profile and any of the calculated centroids. Twelve
samples (5 IBC and 7 non-IBC) were closer to the
luminal A centroid, 5 (1 IBC and 4 non-IBC) to
the luminal B centroid, 9 (6 IBC and 3 non-IBC) to the
basal-like centroid, 2 (2 IBC and 0 non-IBC) to
the ErbB2-overexpressing centroid, and 6 (2 IBC and 4
non-IBC) to the normal-like centroid. There was a
good agreement between these assignments and protein
expression data for ER and CK5/6, a representative
marker for the basal gene cluster. Two out of 11
samples in the combined basal-like and ErbB2-over-
expressing subgroup were ER-positive, whereas 12/23
tumors belonging to the combined luminal A, luminal
B and normal-like cluster were ER-positive (Fisher’s
Exact test, p = 0.063). Six out of 9 samples in the
basal cluster were CK5/6+ whereas only 6 out of 25
samples in the remaining clusters were CK5/6-positive
(Fisher’s Exact test, p = 0.040). A higher amount of
basal-like and ErbB2-overexpressing tumors and a
lower amount of luminal A, luminal B or normal-like
tumors in IBC as compared to non-IBC was found. In
IBC, 8/16 samples (50%) belonged to the combined
basal-like and ErbB2-overexpressing cluster compared
to only 3/18 non-IBC samples (16.7%). However, 15/
18 non-IBC samples (83.3%) belonged to the combined
luminal A, luminal B and normal-like cluster compared
to 8/16 IBC samples (50%) (Pearson v2, p = 0.038).
This was in contrast with the results of Bertucci et al.
[24]: 19/36 IBC samples (52.8%) belonged to the
combined luminal A, luminal B and normal-like cluster
compared to 18/32 non-IBC samples (56.3%). 17/36
IBC samples (47.2%) belonged to the combined
ErbB2-overexpressing and basal-like tumors compared
to 14/32 non-IBC samples (43.7%) (Pearson v2,
p = 0.774).
We applied hierarchical clustering to the expression
levels of 144 genes in our series of 16 IBC and 18 non-
IBC samples. Results are shown in Figure 2. We
identified two major groups and four subgroups related
to the cell-of-origin subtype: normal-like, luminal A,
luminal B and basal-like. No ErbB2-overexpressing
subgroup was identified, probably due to the low
number of samples correlated with the ErbB2-overex-
pressing centroid. The two major groups identified
were in close agreement with the immunohistochemis-
try status for ER: in the left group 10 out of 16 sam-
ples (62.5%) were ER-positive whereas in the right
group 4 out of 18 samples (22.2%) were ER-positive
(Pearson v2, p = 0.01). Four samples were not as-
signed to any subgroup, 2 of which were weakly cor-
related to a centroid. There was a strong association
between the grouping of samples and the centroid they
were closer to. In the left group, 4 out of 6 normal-like
samples and 10 out of 12 luminal A samples clustered
together. In the right group, 4 out of 5 luminal B
samples and 5 out of 9 basal-like tumors clustered
together. The luminal B subgroup was characterized by
the presence of 2 samples, closely correlated with both
the basal-like and the luminal B centroid, but desig-
nated basal-like due to a stronger correlation coeffi-
cient between these samples and the basal-like centroid.
The basal-like subgroup was entirely composed of IBC
specimens. The five cell-of-origin subtypes concerned
all samples, the IBC samples were intermingled with
the non-IBC samples across most subgroups. This
indicates that the different cell-of-origin subtypes are
present in both IBC and non-IBC.
Robustness of the taxonomy
To test for the robustness and reliability of the cell-of-
origin classification, we performed an unsupervised
analysis using an alternative gene set. Based upon our
previous cell-of-origin classification, genes were selected
by comparing each cell-of-origin subtype with the oth-
ers, using a discriminating score combined with per-
mutations tests. Due to the low number of samples
correlated with the ErbB2-overexpressing centroid,
permutation testing for any comparison involving the
ErbB2-overexpressing subgroup was unstable and
the ErbB2-overexpressing subgroup was left out of
the analysis. We developed a molecular signature dis-
criminating between the four centroid-based subtypes by
selecting at most 15 top-ranked discriminating genes in
each comparison. In this way, we identified 141 genes as
discriminatory between the four subtypes.
This list of discriminator genes was then submitted to
hierarchical clustering. Results are shown in Figure 3.
We identified two major groups and four major sub-
groups, in close agreement with the clustering reported
in Figure 2. The left branch was mainly composed of
ER-positive samples (10/16), whereas in the right branch
ER-negative samples (10/13) were predominant (Pear-
son v2, p = 0.03). Three samples were not assigned to a
specific subgroup, two of which showed low correlation
with any of the four cell-of-origin centroids. The left
branch was characterized by the presence of both the
luminal A and the normal-like subgroup. Eleven out of
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12 luminal A samples and 4 out of 6 normal-like samples
clustered together on terminal branches. The right
branch was characterized by the presence of both the
basal-like cluster and the luminal B cluster. Six out of 9
basal-like samples and 4 out of 5 luminal B samples
clustered together on terminal braches. The luminal B
subgroup was again characterized by the presence of the
same 2 samples, closely correlated with both the basal-
like and the luminal B centroid, but designated basal-
like due to a stronger correlation coefficient between
these samples and the basal-like centroid. All of the
samples present in the basal-like subgroup were IBC.
Figure 2. Hierarchical clustering revealing relationships among samples in the data set of 16 IBC and 18 non-IBC specimen using 200 clones
representing 144 genes common to the intrinsic gene set and our cDNA chip. Data are represented in a matrix format with rows representing
genes and columns representing samples. The expression level of each gene is relative to its median across all samples, and is color coded red or
green indicating genes above and below the median expression level, respectively. The magnitude of deviation from the median is represented by
the color saturation. Grey represents genes with missing data. Based on the expression pattern of 144 genes, four out of five cell-of-origin subtypes
were identified. No ErbB2-overexpressing cluster was evident, possibly due to a low number of ErbB2-overexpressing samples. The clusters are
indicated by the colored branches beneath the dendrogram: luminal A (blue), normal-like (red), luminal B (green), and basal-like (yellow). Within
each cluster, branches of the samples are color coded according to the expression centroid they were closest to.
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Overall, 25 out of 32 (78%) samples clustered on
terminal branches, correctly identifying the four differ-
ent cell-of-origin subtypes present in our series of breast
tumors, independently of the IBC or non-IBC pheno-
type.
Contribution of the cell-of-origin subtypes to the IBC
phenotype
To evaluate the contribution of each cell-of-origin
subtype to the amount of variability seen in the entire
Figure 3. Hierarchical clustering revealing relationships among samples in the data set of 16 IBC and 18 non-IBC specimen using 141 genes
selected by comparing four subgroups with each other by using a discriminating score and iterative random permutation testing. Data are
represented in a matrix format with rows representing genes and columns representing samples. Expression level of each gene is relative to its
median across all samples, and is color coded red or green indicating genes above and below the median expression level, respectively. The
magnitude of deviation from the median is represented by the color saturation. Grey represents genes with missing data. Based on the expression
pattern of 141 genes, four cell-of-origin subtypes were identified by using unsupervised hierarchical clustering using an alternative gene set, hereby
demonstrating the robustness of the taxonomy. The clusters are indicated by the colored branches beneath the dendrogram: luminal A (orange),
normal-like (red), luminal B (green), and basal-like (yellow).
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data set, we executed a principal component analysis
for the five molecular subtypes on a gene list with 5914
non-batch-related genes. Since there are never more
principal components than there are conditions in the
data, we identified five principal components (PC):
PC1, PC2, PC3, PC4, and PC5 accounting for,
respectively, 65.2, 17.5, 8.9, 5.5, and 3.0% of the entire
variability seen in the data set. The expression patterns
of each principal component are pictured in Figure 4.
Four out of five principal components have an
expression pattern that is clearly linked to the cell-of-
origin subtypes: PC2 shows a peak expression for the
normal-like cell-of-origin subtype, PC3 is high in
ErbB2-overexpressing tumors and low in luminal B
tumors, PC4 is high in luminal A tumors and slightly
elevated in basal-like tumors, and PC5 is most pro-
nounced in basal-like tumors. PC1 was elevated in all
cell-of-origin subtypes but was not specifically associ-
ated with a particular cell-of-origin subtype. We then
executed an unsupervised hierarchical clustering on our
set of 16 IBC and 18 non-IBC specimens, using 719
genes with gene expression patterns strongly correlated
(r>0.95) to PC1. This identified two main branches,
left and right. The left branch was entirely composed
of IBC specimens (13/13), whereas the right branch
was mainly composed of non-IBC specimens (18/21)
(Pearson v2, p<0.0001). In contrast, unsupervised
hierarchical clustering of our 16 IBC and 18 non-IBC
specimens, using the entire gene set of 5914 not batch
related genes did not clearly separate IBC and non-IBC
specimen. This indicates that most of the variability
(65.2%) seen in the entire data set of not batch related
genes is attributable to the distinction between IBC and
non-IBC. Overall, gene expression patterns related to
the different cell-of-origin subtypes explain 34.8% of
the variability seen within this data set. Hierarchical
clustering using genes with gene expression patterns
strongly correlated (r>0.95) to PC2 revealed a cluster
with normal-like samples (normal-like samples in:
normal-like cluster: 4/4 versus non-normal-like cluster:
2/30; Pearson v2, p<0.0001). This agrees with the
observation that the expression pattern of PC2 is spe-
cifically pronounced in the normal-like cell-of-origin
subtype. Similarly, a luminal B cluster (luminal B
Figure 4. Principal component analysis for each of the cell-of-origin subtypes using a data set with gene expression data from 5914 genes in 16
IBC and 18 non-IBC specimens. Principal component analysis identified five principal components. The gene expression patterns and the
associated gene expression data of the principal components (PC) across the different cell-of-origin subtypes are represented in (a): PC1 (red), PC2
(orange), PC3 (yellow), PC4 (green), and PC5 (blue). The principal components account for respectively 65.18, 17.49, 8.86, 5.51, and 2.97% of the
total variance obsereved in the data set. Four out of five principal components have an expression pattern that is linked to the cell-of-origin
subtypes: PC2 shows a peak expression for the normal-like cell-of-origin subtype, PC3 is high in ErbB2-overexpressing tumors and low in luminal
B tumors, PC4 is high in luminal A tumors and slightly elevated in basal-like tumors, PC5 is most pronounced in basal-like tumors. PC1 was
elevated in all cell-of-origin subtypes but was not specifically associated to any cell-of-origin subtype. Gene expression data for each principal
component in each cell-of-origin subtype are pictured in (b). Unsupervised hierarchical clustering using a gene set with genes that are strongly
correlated (r>0.95) to PC1 was executed to investigate the relationships among samples present in this data set. This revealed that most of the
variation seen in this data set is attributable to the distinction between IBC and non-IBC (c).
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samples in: luminal B cluster: 4/6 versus non-luminal B
cluster: 1/28; Fisher’s Exact, p = 0.002), a combined
basal-like and luminal A cluster (basal-like and luminal
A samples in: combined basal-like and luminal A
cluster: 15/16 versus combined luminal B, normal-like
and ErbB2-overexpressing cluster: 6/18; Pearson v2,
p<0.0001), and a basal-like cluster (basal-like samples
in: basal-like cluster: 6/9 versus non-basal-like cluster:
3/25; Fisher’s Exact, p = 0.004) were observed when
using a gene list with genes closely correlated with,
respectively, PC3, PC4, and PC5.
To evaluate the contribution of each of the cell-of-
origin subtypes to the IBC phenotype, a PCA for the
five molecular subtypes using a gene list with 953 genes
with a statistically significant (p<0.05) 1.5-fold, dif-
ference in expression in IBC and non-IBC was per-
formed. Again five principal components were
identified: PC1, PC2, PC3, PC4, and PC5 explaining,
respectively, 70.54, 11.64, 10.96, 3.98, and 2.88% of the
variability seen in the data set. Figure 5 shows the
expression pattern associated with each of the principal
components. PC3 and PC5 clearly have a peak
expression in the normal-like and basal-like subgroup,
respectively. PC2 has a peak expression in the ErbB2-
overexpressing subgroup and a low expression in the
luminal B subgroup. PC4 is characterized by a peak
expression in both the luminal B and the ErbB2-over-
expressing subgroups and a reduced expression in the
luminal A subgroup. However, the principal compo-
nent, accounting for more than 70% of the variability
seen in this data set does not show a pronounced
expression in any of the cell-of-origin subtypes.
Therefore, the different cell-of-origin subtypes together
account for less than 30% of the variability seen
between IBC and non-IBC.
Discussion
In this study we have analyzed the presence of different
cell-of-origin subtypes in IBC. The different cell-of-ori-
gin subtypes have been repeatedly observed in non-IBC
[2,3,4] but only once in IBC [24]. Expression centroids
were calculated for each of the five cell-of-origin sub-
types, by using 144 genes common to our cDNA chip
and the intrinsic gene set defined by Sorlie et al. [4].
Using these expression centroids, our samples were
classified by calculating correlation coefficients between
each sample and each centroid. Classification was vali-
dated by unsupervised hierarchical clustering and
robustness was shown by classifying our samples using
an alternative gene set. Our results showed that different
cell-of-origin subtypes are present in IBC but the com-
bined ErbB2-overexpressing and basal-like subtype was
significantly more prevalent in IBC in comparison to
non-IBC. Taking into account the poor clinical outcome
associated with these cell-of-origin subtypes, this
observation agrees with the fact that IBC is character-
ized by a poor 3-year survival rate of only 40%, com-
pared to 85% in non-IBC [8]. Univariate survival
analysis comparing the cell-of-origin subtypes with re-
spect to overall survival showed a highly significant
difference, with the basal-like and ErbB2-overexpressing
clusters associated with the shortest survival times.
Similar results were obtained with respect to relapse-free
survival [3]. These observations were repeated in other
patient cohorts by performing univariate Kaplan–Meier
analysis with time to development of distant metastasis
as a variable. The probability of remaining disease-free
was significantly different between the subtypes, with
metastasis-free survival times being significantly shorter
in basal-like and ErbB2-overexpressing subtypes [4].
Figure 5. Principal component analysis for each of the cell-of-origin subtypes using a data set with gene expression data from 969 genes with a
significant (p < 0.05) different expression of 1.5 between IBC and non-IBC specimens. Principal component analysis identified five principal
components (PC). The gene expression patterns and the associated gene expression data of the principal components across the different cell-of-
origin subtypes are represented in (a): PC1 (red), PC2 (orange), PC3 (yellow), PC4 (green), and PC5 (blue). The principal components account for
respectively 70.54, 11.64, 10.96, 3.98, and 2.88% of the total variance observed in the data set. Four out of five principal components have an
expression pattern that is clearly linked to the cell-of-origin subtypes: PC2 shows a peak expression for the ErbB2-overexpressing cell-of-origin
subtype and low expression in the luminal B subtype, PC3 is high in the normal-like tumors, PC4 is elevated in ErbB2-overexpressing and luminal
B tumors and reduced in luminal A tumors, PC5 is most pronounced in basal-like tumors. PC1 was elevated in all cell-of-origin subtypes but was
not specifically associated to any cell-of-origin subtype. Gene expression data for each principal component in each cell-of-origin subtype is
pictured in (b).
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Kaplan–Meier survival analysis of 829 cases immuno-
histochemically stained for CK5/6 and cytokeratin 17
(CK17), two markers of the basal-like cell-of-origin
subtype, showed that positivity for either of these basal
markers correlated with shorter disease-specific survival
than for negative cases. Positivity for either of these
basal markers was also associated with a significantly
poorer outcome in the lymph node positive group,
whereas in the lymph node negative group a trend to-
wards statistical significance was observed [27]. In the
same study, HER1 protein expression was observed to
correlate well with the expression of CK5/6 and CK17
and was associated with poor survival. It has been de-
scribed that EFGR transcripts were observed more
frequently in IBC than in non-IBC [8,28]. Another
molecular marker implicated in breast cancer is TP53,
mutated in approximately 30% of breast tumors.
Mutations are more frequently observed in advanced-
stage breast cancer and/or aggressive breast cancer.
Likewise, TP53 is mutated more often in the IBC com-
pared to the non-IBC [8]. The fraction of tumors with
TP53 mutations was significantly differenent in the cell-
of-origin subtypes, with higher mutation frequencies in
the ErbB2-overexpressing and basal-like tumor groups
[3]. Altogether, the basal-like subtype of breast cancer
may represent a distinct clinical entity and is generally
characterized by expression of a set of markers also
expressed in IBC. Moreover, expression of EGFR and
KIT, another marker associated with the basal-like cell-
of-origin subtype [27], correlates with mesenchymal and
myoepithelial differentiation of tumor cells [29]. This
suggests the intriguing possibility that the tumors
belonging to the basal-like subgroup are tumors that
acquire the basal-like characteristics through a process
of transdifferentiation. Plasticity of human breast car-
cinoma has been investigated and it has been shown that
breast cancer cell lines can acquire a myofibroblastic
phenotype through epithelial-to-mesenchymal transition
(EMT), a process in which tumor cells loose their epi-
thelial phenotype and acquire a more motile and inva-
sive phenotype [30,31,32]. This can explain the poor
prognosis associated with the breast basal-like sub-
group. We have preliminary data, indicating that EMT
is a process more active in IBC in comparison to non-
IBC. It has also been shown that the transcription factor
NF-kappaB is important for induction and maintenance
of EMT [33,34]. This agrees with our previous findings
indicating that NF-kappaB plays a major role in the
biology of IBC [23].
Although the presence of different molecular sub-
types in IBC and non-IBC is unquestionable, the indi-
vidual classification of samples based on the expression
of our gene set of 144 genes should be taken with care.
When classifying the remaining samples in the Norway/
Stanford data set, not considered for calculation of the
expression centroids, 30% of these samples were mis-
classified using the centroid classification method. Par-
ticularly luminal B and normal-like samples were often
closer to the wrong cell-of-origin centroid. This can be
explained by the fact that in our reduced gene set of 144
genes, few markers for the luminal B and normal-like
cell-of-origin subtype are present, since no specific gene
cluster for these subgroups was observed. Alternatively,
one can also reason that the classification power of the
expression centroids is more pronounced in more
homogeneous subgroups, e.g. basal-like and ErbB2-
overexpressing subtypes, than in less homogeneous
subgroups, e.g. luminal A, luminal B and normal-like.
While classifying the 16 IBC and 18 non-IBC samples,
several samples were often significantly correlated with
more than one expression centroid. This suggests a
strong relationship between the cell-of-origin subtypes.
Basal-like and ErbB2-overexpressing samples are usu-
ally correlated with each other and anti-correlated with
luminal A samples. Conversingly, luminal A samples are
usually anti-correlated with basal-like and ErbB2-over-
expressing samples. Luminal A and luminal B specimens
are often correlated with each other and occasionally
luminal B samples are correlated with basal-like sam-
ples, as indicated by the hierarchical clustering pattern
(Figures 2 and 3). This can be explained by the
hypothesis that basal-like and luminal B tumors arise
from transformation of the most primitive ER-negative
stem cell/early progenitor cell, but luminal B specimens
become ER-positive through additional mutations,
hence their correlation with the ER-positive luminal A
subtype. Nevertheless, ER expression remains hetero-
geneous in luminal B samples, as evidenced by the
weaker expression of the ER gene cluster [7].
Despite the presence of different cell-of-origin sub-
types in IBC, as was reported by Bertucci et al. [24], we
identified a higher fraction of ErbB2-overexpressing and
basal-like samples and a lower fraction of luminal A,
luminal B and normal-like samples in IBC in comparison
with non-IBC. This is in contrast to the results published
by Bertucci et al. [24], where no difference was observed
between IBC and non-IBC for the combined ErbB2-
overexpressing and basal-like and the combined luminal
A, luminal B and normal-like clusters. This discrepancy
can be, in part, explained by platform differences but the
main reason is probably lack of rigidity in diagnosing IBC
in the study of Bertucci et al. [24]. Diagnosis in their study
is based on clinical ‘and/or’ pathological criteria, while
strict adherence to the TNM classification of the Ameri-
can Joint Committee on cancer [9] was adopted in our
study. The diagnosis based on clinical ‘and/or’ patho-
logical criteria resulted in the absence of non-IBC tumors
with dermal lymphatic emboli, whereas it is well known
that dermal lymphatic invasion can be associated with all
breast carcinoma subtypes. Even more, IBC can reliably
be diagnosed in the absence of dermal lymphatic emboli
[8]. Therefore, it might be that some non-IBC samples
have been misclassified as IBC samples due to the pres-
ence of dermal lymphatic emboli. This hypothesis is even
further strengthened by the observation of a high number
of ER-positive IBC samples, whereas IBC is reported to
be more frequently ER-negative than non-IBC. Up to
60% of IBC tumors lack hormone receptor expression,
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whereas other forms of LABC are more likely to be ER-
positive [8]. In the study of Bertucci et al. [24] overall,
56% (20/36) of the IBC samples showed ER-positivity,
whereas only 31% (5/16) of the IBC specimen in our study
were positive for ER. There was a statistical significant
difference when comparing the fraction of ER-positive
IBC samples in the combined luminal A, luminal B and
normal-like cluster between both studies.We reported 4/8
(50%) ER-positive IBC samples in the combined luminal
A, luminal B and normal-like cluster, whereas all IBC
samples in the corresponding cluster reported by Bertucci
et al. [24] were ER-positive (Fisher’s Exact test,
p = 0.004). This suggests that some of the ER-positive
‘IBC’ samples in the study by Bertucci et al. [24] might be
non-IBC with emboli in dermal lymph vessels.
The identification of the cell-of-origin subtypes in the
IBC gene expression pattern does not exclude the spe-
cific molecular nature of IBC. Based on the expression
of 756 differentially expressed genes, we were able to
separate IBC from non-IBC specimen. This clustering
was not based on the expression of ER- and ErbB2-
related molecules, since these genes were filtered out
prior to performing the clustering analysis. A class
prediction algorithm based on 50 differentially expressed
genes was able to correctly classify 14/16 (86%) IBC and
non-IBC specimens [23]. Bertucci et al. [24] described a
109-gene signature that discriminates IBC from non-
IBC with an accuracy rate of 84% [22]. We have shown
by principal component analysis, that the different cell-
of-origin subtypes explain approximately 30% of the
variation between IBC and non-IBC. This agrees with
the observation that IBC specimens more often express
markers related to the basal-like and ErbB2-overex-
pressing tumors, whereas non-IBC specimens more of-
ten express markers related to the combined luminal A,
luminal B and normal-like cluster. If no difference
would have been found between IBC and non-IBC for
the cell-of-origin subtypes, markers representative for
the different cell-of-origin subtypes would be absent in
the gene list with differentially expressed genes in IBC
and non-IBC. Hence no principal components with a
cell-of-origin subtype specific expression pattern would
have emerged. On the other hand, 70% of gene
expression differences of IBC and non-IBC cannot be
explained by cell-of-origin subtype specific expression
patterns. This was corroborated by principal component
analysis on a gene list not enriched in differentially ex-
pressed genes between IBC and non-IBC. In this data
set, 65% of the total variance seen, was explained by
other differences between IBC and non-IBC than those
related to cell-of-origin subtype, as evidenced by the
hierarchical clustering analysis with genes strongly cor-
related to the first principal component.
In conclusion, the present data support previous re-
sults indicating that IBC and non-IBC have to be re-
garded as separate breast cancer types [22,23], with a
phenotype largely defined by a distinct gene expression
profile independent of the cell-of-origin subtypes, al-
though the latter contribute: a significantly higher frac-
tion of IBC than non-IBC belongs to the basal-like and
ErbB2-overexpressing subtypes.
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